All studies
Phase not statedRecruitingInterventionalNCT07893002

A Randomized, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study

An Investigator-Initiated Extension Study to Evaluate Maintenance of Remission, Prevention of Relapse, and Long-Term Safety of CreNeuroS™ CNS Fish Oil Plus Softgels in Subjects With Major Depressive Disorder Who Complete the Acute Treatment Phase of Protocol VRL-CT-26-006

  • Adjunct in the Treatment of Depressive Disorder
I want to take partRefer a patient1 site in India · 1 worldwide

At a glance

Phase
Phase not stated
Study type
Interventional
Sponsor
Sichuan Credit Pharmaceutical Co., Ltd.
Enrolment target
60
Started
11 September 2026
Main results due (estimated)
October 2027
Study ends (estimated)
October 2027
Allocation
Randomized
Design
Parallel
Purpose
Supportive care
Masking
None
Sites
1 · 1 in India
First posted
23 October 2026
Registry updated
3 November 2026

Eligible subjects who successfully complete the acute treatment phase of Protocol VRL-CT-26-006, achieve remission, and provide written informed consent will be randomized in a 1:1:1 ratio

Can you take part?

  • No age limit is stated.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: child, adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

1. Subject has completed the 8-week treatment phase of the parent study and achieved remission, defined as HAM-D-17 ≤7 at Week 8.
2. Subject is clinically stable at the time of entering the transition/taper period, with no clinically significant worsening of depressive symptoms requiring immediate therapeutic intervention.
3. Investigator considers tapering and discontinuation of Escitalopram clinically appropriate and safe for the subject.
4. Subject completes the protocol-defined Escitalopram taper/transition period without experiencing relapse or clinically significant worsening of depressive symptoms requiring therapeutic intervention.
5. Following completion of the transition period, subject remains clinically suitable for participation based on Investigator assessment, including depressive symptoms and overall clinical status, and has not experienced relapse during the transition/taper period.
6. Subject does not require continuation, reinstatement or initiation of antidepressant therapy at the time of extension enrollment, except protocol-permitted rescue treatment where applicable.
7. Subject has no clinically significant adverse event, serious adverse event, or new medical/psychiatric condition that would preclude participation.
8. Subject is willing and able to comply with the 52-week maintenance visits, assessments, treatment requirements and other study procedures.
9. Subject provides written informed consent for participation in the Extension/Maintenance Phase before undertaking any extension-specific study procedure.
10. Subject is considered medically and psychiatrically suitable for participation in the 52-week extension by the Investigator.

Exclusion Criteria:

1. HAM-D-17 score \>7 at Week 8 of the parent study.
2. Clinically significant worsening of depressive symptoms during the Escitalopram taper/transition period that, in the Investigator's opinion, makes participation inappropriate.
3. Subject meets the protocol-defined criteria for relapse during the transition/taper period or before extension enrollment.
4. Subject requires continuation, reinstatement or initiation of antidepressant therapy due to clinical deterioration.
5. Clinically significant Escitalopram discontinuation/withdrawal symptoms requiring continued antidepressant treatment or otherwise precluding participation in the extension.
6. Any ongoing clinically significant adverse event or serious adverse event that may compromise subject safety or interfere with assessment of the extension outcomes.
7. Any new or worsening medical or psychiatric condition that, in the Investigator's opinion, makes the subject unsuitable for participation.
8. Emergence of clinically significant suicidal ideation, suicidal behaviour or other safety concern requiring therapeutic intervention or a higher level of psychiatric care.
9. Major protocol deviation during the parent study that, in the Investigator's opinion, may affect subject safety or the reliability of the extension assessments.
10. Requirement for prohibited concomitant medications or therapies that may interfere with the study assessments.
11. Pregnancy, planned pregnancy during the extension period, or breastfeeding, as applicable.
12. Significant non-compliance with study procedures, treatment or visits during the parent study that raises concern regarding the subject's ability to comply with the extension.
13. Subject withdraws consent or is unwilling to continue participation.
14. Subject is unlikely to be available for the required 52-week follow-up or unable to comply with the study procedures.
15. Any other condition or circumstance that, in the Investigator's judgment, makes the subject unsuitable for participation or places the subject at unacceptable risk.

Relapse is defined as meeting ALL of the following criteria simultaneously: (1) HAM-D-17 score ≥18; (2) and an increase of ≥50% from the baseline score; (3) and hospitalization or adjustment of antidepressant treatment (e.g., change in medication) due to worsening depressive symptoms, as determined by the Investigator.

What this study is about

In the sponsor’s own words, from the registry.

This multicenter, randomized, open-label extension study will evaluate the maintenance of remission, relapse prevention, long-term clinical outcomes, and safety of CreNeuroS™ in participants with Major Depressive Disorder (MDD) who achieve protocol-defined remission (HAM-D-17 score ≤7) following completion of the 8-week acute treatment phase of parent study VRL-CT-26-006.

Eligible participants who remain clinically stable and provide written informed consent for the extension study will undergo a transition/taper period of approximately 2 weeks, which may be extended to 4 weeks if clinically warranted. No extension study intervention will be administered during this period.

Following the transition/taper period, eligible participants will be randomized in a 1:1:1 ratio to one of three maintenance groups: (1) observation without CreNeuroS™ supplementation; (2) CreNeuroS™ CNS Fish Oil Plus Softgels, one capsule orally once daily; or (3) CreNeuroS™ CNS Fish Oil Plus Softgels, two capsules orally once daily. Participants will be followed for 52 weeks after extension baseline to assess maintenance of remission, relapse, clinical outcomes, and safety.

Read the detailed description

The parent study had randomized 80 subjects. Based on the anticipated remission rate following the 8-week acute treatment phase, it is expected that approximately 50 to 70 subjects will be eligible for participation in the extension phase. The actual number of subjects enrolled will depend on the observed remission rate, subject willingness to continue participation, and investigator assessment of eligibility.

The extension phase is intended to generate long-term evidence on the maintenance of remission, prevention of relapse, and long-term safety of CreNeuroS™ CNS Fish Oil Plus Softgels.

What participants receive

  • Other

    Group A- Observation without CreNeuroS™ supplementation

    Observation without CreNeuroS™ supplementation

    Other: No intervention

  • Experimental

    Group B- CreNeuroS™ CNS Fish Oil Plus Softgels, 1 capsules orally once daily.

    CreNeuroS™ CNS Fish Oil Plus Softgels, 1 capsules orally once daily.

    Dietary Supplement: CreNeuroS™ CNS Fish Oil Plus Softgels, 1 capsule orally once daily

  • Experimental

    Group C- CreNeuroS™ CNS Fish Oil Plus Softgels, 2 capsules orally once daily

    CreNeuroS™ CNS Fish Oil Plus Softgels, 2 capsules orally once daily

    Dietary Supplement: CreNeuroS™ CNS Fish Oil Plus Softgels, 2 capsule orally once daily

Interventions

  • No interventionOther

    No CreNeuroS™ supplementation;

  • CreNeuroS™ CNS Fish Oil Plus Softgels, 1 capsule orally once dailyDietary supplement

  • CreNeuroS™ CNS Fish Oil Plus Softgels, 2 capsule orally once dailyDietary supplement

What the study measures

Primary outcomes

  1. Efficacy End point- Proportion of subjects remaining relapse-free during the 52-week maintenance period

    Proportion of subjects remaining relapse-free during the 52-week maintenance period, where relapse is defined as meeting ALL of the following criteria simultaneously: (1) HAMD-17 total score ≥18; (2) and an increase of ≥50% from the baseline score; (3) and hospitalization or adjustment of antidepressant treatment (e.g., change in medication) due to worsening depressive symptoms, as determined by the Investigator.

    Time frame: Week 0, Weeks 12, 26, 40, and 52, based on HAM-D-17 score.

Secondary outcomes

  1. Safety end point- Incidence, severity and relatedness of AEs/SAEs, treatment discontinuations due to AEs, vital signs and other clinically relevant safety assessments.

    Incidence, severity and relatedness of AEs/SAEs, treatment discontinuations due to AEs, vital signs and other clinically relevant safety assessments.

    Time frame: Week 0, Weeks 12, 26, 40, and 52

Who is running it

Lead sponsor
Sichuan Credit Pharmaceutical Co., Ltd.
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Sichuan Credit Pharmaceutical Co., Ltd.
Collaborators
Vivotech Research Lab Pvt Ltd
Data monitoring committee
No
US FDA-regulated drug
No
US FDA-regulated device
No
Sponsor's study ID
VRL-CT-26-006, Version 2.0

Study sites(1)

Showing 1 of 1 sites. 1 recruiting, 0 not recruiting and 0 cancelled; 1 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

  • Sinha S, Chary S, Thakur P, Talluri L, Reddy M, Verma KK, Saha P, Gupta VB, Ramaiah KA, Khanum SZ. A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder. Cureus. 2021 Jul 28;13(7):e16689. doi: 10.7759/cureus.16689. eCollection 2021 Jul. PMID 34513348
Participant data shared
Undecided

Source: ClinicalTrials.gov record NCT07893002, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.